Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
NCT03732794 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.
Conditions Studied
Interventions
- DEVICE AtriCure CryoICE & AtriClip LAA Exclusion
Study Locations (15)
New York
- Mount Sinai Icahn School of Medicine — New York
- NYP-Weill Cornell — New York
- Northwell Health Systems — New York
- St. Joseph Hospital Health Center — Syracuse
Indiana
- Franciscan Health — Indianapolis
- Deaconess Gateway Hospital — Newburgh
California
- UCLA Medical Center — Los Angeles
District of Columbia
- Washington Adventist Hospital — Washington D.C.
Illinois
- Northwestern Medicine — Chicago
Maryland
- University Of Maryland — Baltimore
Michigan
- University of Michigan — Ann Arbor
Minnesota
- Mayo Clinic — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732794
The ClinicalTrials.gov registry entry for NCT03732794 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention — of which AtriCure CryoICE & AtriClip LAA Exclusion is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03732794 reports 15 study locations spanning 11 distinct geographic areas — top geographies include New York, Indiana, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03732794 about?
NCT03732794 is a clinical study titled "AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment". The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.
What is the current status of trial NCT03732794?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2019-01-30. Estimated completion is 2026-06.
What conditions does trial NCT03732794 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03732794?
The interventions under investigation include: AtriCure CryoICE & AtriClip LAA Exclusion (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03732794?
This trial is sponsored by AtriCure, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03732794 being conducted?
This trial has 15 study locations across California, District of Columbia, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.